GlassScriptPhysician profile
Evangelos Moraitis
NPI 1619950144
$5,205.17
in general payments reported to CMS, 2019-2025
35 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $245 · 2021: $192 · 2022: $466 · 2023: $1,148 · 2024: $1,258 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,804 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.64 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $633.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $453.71 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $425.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.63 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $379.64 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $362.30 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $313.56 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $287.74 | 2019-2025 | |
| Pfizer INC. | $240.73 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $226.58 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $196.15 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.56 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $159.82 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $152.03 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $119.87 | 2023-2024 | Gvoke Hypopen |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $88.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $81.52 | 2022-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $77.19 | 2023-2025 | Gemtesa |
| Antares Pharma, INC. | $60.92 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $59.44 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $39.66 | 2019-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $37.33 | 2025 | Auvelity, Symbravo |
| Mylan Specialty L.P. | $35.71 | 2023 | Yupelri |
| Edwards Lifesciences Corporation | $28.75 | 2025 | Sapien 3 Ultra Resilia |
| Daiichi Sankyo INC. | $28.04 | 2023 | Injectafer |
| Globus Medical, INC. | $21.76 | 2025 | Vyrsa V1 |
| Inspire Medical Systems, INC. | $21.65 | 2025 | Inspire |
| Shield Therapeutics INC | $21.36 | 2024 | |
| Dynavax Technologies Corporation | $20.51 | 2024 | Heplisav-B |
| Mirum Pharmaceuticals, INC. | $19.82 | 2024 | Cholbam |
| Eisai INC. | $18.72 | 2020 | |
| Medtronic Minimed, INC. | $12.76 | 2020 | |
| Phathom Pharmaceuticals, INC. | $12.22 | 2025 | Voquezna |
| Medtronic USA, INC. | $11.64 | 2019 | |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evangelos Moraitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.